Denali Therapeutics (DNLI) Liabilities and Shareholders Equity (2017 - 2026)

Denali Therapeutics (DNLI) has reported Liabilities and Shareholders Equity for 10 consecutive years, with $1.3 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity changed 0.42% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $4.6 billion (down 17.3% YoY), while the FY2025 annual figure was $1.1 billion, down 16.69% from the prior year.
• Liabilities and Shareholders Equity grew to $1.3 billion in Q1 2026 per DNLI's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.6 billion in Q1 2024 and bottomed at $1.1 billion in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $1.3 billion across 5 years, with a median of $1.3 billion in 2022.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity gained 19.09% — and 2025, when it declined 27.4%.
• Denali Therapeutics' Liabilities and Shareholders Equity stood at $1.5 billion in 2022, then retreated by 20.98% to $1.2 billion in 2023, then increased by 19.09% to $1.4 billion in 2024, then declined by 16.69% to $1.1 billion in 2025, then advanced by 10.58% to $1.3 billion in 2026.
• Business Quant data shows DNLI's Liabilities and Shareholders Equity at $1.3 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.1 billion in Q3 2025.